Impact of HIV impact on outcomes of deep‐brain stimulation of the subthalamic nucleus for Parkinson's disease. (19th January 2022)

• Record Type: Journal Article
• Authors: Garcia, Jeanne; Hubsch, Cécile; Marques, Ana; Gurruchaga, Jean‐Marc; Lamirel, Cédric; Roze, Emmanuel; Moulignier, Antoine
• Is Part Of: European journal of neurology. Volume 29:Number 4(2022)
• Page Start: 1232
• Page End: 1237
• Publication Date: 2022-01-19
• Subjects: AIDS -- deep‐brain stimulation -- HIV -- Parkinson's disease -- subthalamic nucleus; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.15240
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract: Background and purpose: Middle‐aged persons living with HIV (PLHIV) have a heightened risk of more concomitant age‐related comorbidities that are acknowledged as signs of poorer prognosis after deep‐brain stimulation of the subthalamic nucleus (STN‐DBS) at younger‐than‐expected ages. To assess the beneficial and adverse effects of STN‐DBS in PLHIV with Parkinson's disease (PD). Methods: We retrospectively included nine PLHIV with PD who had sustained virological control. Patients were followed up for 7 ± 4 years. Results: Patients' mean ages at PD onset and STN‐DBS were 45 ± 15 and 53 ± 16 years, respectively. At STN‐DBS, mean HIV infection and PD durations were 15 ± 12 and 8 ± 4 years, respectively. STN‐DBS significantly improved 1‐year Unified Parkinson's Disease Rating Scale (UPDRS)‐III scores (71%), daily off‐time (63%), motor fluctuations (75%) and daily levodopa‐equivalent dose (68%); mean 5‐year UPDRS‐III score and motor fluctuation improvements remained ~45%. Impulse control disorders (affecting 6/9 patients) fully resolved after STN‐DBS. Postoperative course was uneventful. No serious adverse events occurred during follow‐up. Conclusion: Our findings indicate that STN‐DBS is a safe and effective treatment for PLHIV with PD.